# EDGAR Filing Document

**Accession Number:** 0001567529
**File Stem:** 0001213900-23-020112
**Filing Date:** 2023-3
**Character Count:** 32366
**Document Hash:** 30c57639196f97ba65271f8581a10e47
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-020112.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001213900-23-020112

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230315

**FILED AS OF DATE**: 20230315

**DATE AS OF CHANGE**: 20230315

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KAMADA LTD
- **CENTRAL INDEX KEY:** 0001567529
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35948
- **FILM NUMBER:** 23733256

**BUSINESS ADDRESS:**
- **STREET 1:** 2 HOLTZMAN ST., SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670402
- **BUSINESS PHONE:** 97289406472

**MAIL ADDRESS:**
- **STREET 1:** 2 HOLTZMAN ST., SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670402

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16**

**of the Securities Exchange Act of 1934**

For the Month of March 2023

Commission File Number 001-35948

**Kamada Ltd.**

(Translation of registrant's name into English)

**2 Holzman Street<br> Science Park, P.O. Box 4081<br> Rehovot 7670402<br> Israel**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-____

**This Form 6-K is being incorporated by reference into the Registrant's Form S-8 Registration Statements, File Nos. [333-192720](http://www.sec.gov/Archives/edgar/data/1567529/000117891313003548/zk1314048.htm), [333-207933](http://www.sec.gov/Archives/edgar/data/1567529/000117891315003362/zk1517560.htm), [333-215983](http://www.sec.gov/Archives/edgar/data/1567529/000117891317000388/zk1719386.htm), [333-222891](http://www.sec.gov/Archives/edgar/data/1567529/000117891318000396/zk1821132.htm), [333-233267](http://www.sec.gov/Archives/edgar/data/1567529/000117891319002187/zk1923409.htm) and [333-265866](http://www.sec.gov/Archives/edgar/data/1567529/000121390022035395/ea161899-s8_kamadaltd.htm).**

The following exhibit is attached:

99.1 [Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth](ea175225ex99-1_kamadaltd.htm)

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 15, 2023 | **KAMADA LTD.** | **KAMADA LTD.** |
|  | By: | /s/ Yifat Philip |
|  |  | Yifat Philip<br> Vice President General Counsel and<br> Corporate Secretary |

---

<u>EXHIBIT INDEX</u>

<u>EXHIBIT NO.</u> <u>DESCRIPTION</u> <br> 99.1 [Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth](ea175225ex99-1_kamadaltd.htm)

## Exhibit 99.1

**Exhibit 99.1**

**Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth** 

● *Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year-over-Year* 

● *Fiscal Year 2022 EBITDA of $17.8 million, Represented Margins of 14%, and a 3x Increase Over Fiscal Year 2021* 

● *Recorded Highest Annual Operating Cash Flow in Kamada's History of $28.6 Million in Fiscal Year 2022; $34.3 Million Cash Position as of December 31, 2022, Nearly Double Cash Position at Year-End 2021* 

● *Fiscal Year 2023 Revenues Expected to be in Range of $138 Million to $146 Million; 2023 EBITDA Anticipated to be in Range of $22 Million to $26 Million; Mid-Point Expected EBITDA Represents Approximately 35% Growth Year-over-Year* 

● *Strong 2022 Results and 2023 Positive Outlook Driven by Multiple Growth Drivers, including CYTOGAM® and KEDRAB® Sales, GLASSIA® Royalties, Other Proprietary Product Sales in International Markets, and Thriving Israeli Distribution Business* 

● *Continued Progress in Ongoing* *InnovAATe, Pivotal Phase 3 Clinical Trial of Inhaled AAT , Including Recruitment Acceleration, Successful DSMB Meeting and Intention to Meet Regulatory Agencies During H1/2023* 

● *Conference Call and Live Webcast with Slides Today at 8:30 AM ET* 

**REHOVOT, Israel, and Hoboken, NJ – March 15, 2023** -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the 12 and three months ended December 31, 2022.

"The success of our rapid strategic transformation to a diversified, fully integrated specialty plasma company is evidenced by our impressive full-year 2022 financial results," said Amir London, Kamada's Chief Executive Officer. "We met our 2022 revenue and profitability guidance, with total revenues of $129.3 million, which represented 25% growth compared to 2021, and EBITDA of $17.8 million, a 3x increase over 2021. Moreover, we generated operating cash flow of $28.6 million during 2022, supporting the increase in our cash position to $34.3 million as of December 31, 2022. These impressive results were driven by our ability to leverage multiple growth drivers, including the portfolio of four FDA approved IgGs acquired in late 2021, the sales of which increased 24% year over year in 2022, KEDRAB sales in the U.S., GLASSIA royalties from Takeda, the sales of our other Proprietary products in the international markets, and our thriving Israeli distribution business," continued Mr. London.

"Importantly, we expect the momentum from 2022 to extend throughout 2023, with profitability to be further enhanced. As such, we are introducing full-year 2023 revenue guidance of $138 million to $146 million and EBITDA guidance of $22 million to $26 million. Mid-point expected EBITDA represents approximately 35% growth year over year. Moreover, our multiple catalysts are anticipated to drive annual double-digit growth in the foreseeable years ahead, with significant upside potential and limited downside risk," concluded Mr. London.

**Financial Highlights for the Year Ended December 31, 2022**

● Total revenues were $129.3 million in the year ended December 31, 2022, as compared to $103.6 million recorded in the year ended December 31, 2021. The increase in revenues was primarily attributable to sales of the acquired four IgG products.

● Gross profit and gross margins were $46.7 million and 36%, respectively, in the year ended December 31, 2022, compared to $30.3 million and 29%, respectively, reported in the year ended December 31, 2021. Gross profit and gross margins in 2022, excluding intangible assets depreciation in the amount of $5.3 million would have been $52.0 million and 40%, respectively, representing a significant increase year-over-year.

● Operating expenses, including R&D, Sales & Marketing (S&M), G&A and other expenses, totaled $42.2 million in the year ended December 31, 2022, as compared to $31.0 million in the prior year. This increase was attributable to an increase in S&M costs associated with the recently acquired portfolio, as well as increased R&D costs, primarily due to advancing the pivotal Phase 3 InnovAATe trial for Inhaled AAT through the opening of new clinical sites and the manufacturing of clinical supply for the study. S&M costs for the year ended December 31, 2022, included $1.7 million of depreciation expenses of intangible assets generated through the IgG products acquisition.

● Finance expense, net for the year ended December 31, 2022, included $6.3 million of expenses associated with the revaluation of the contingent consideration and other long-term liabilities, assumed as part of the IgG products acquisition. For more information with respect to such contingent consideration and other long-term liabilities please refer to Note 5 of the Company's 2022 financial statements included in the 2022 Annual Report on Form 20-F filed on March 15, 2023, with the Securities and Exchange Commission.

● Net loss was $2.3 million, or $(0.05) per share in the year ended December 31, 2022. Excluding depreciation expenses of intangible assets generated through the recent acquisition, and finance expense associated with the revaluation of the contingent consideration and other assumed long-term liabilities, the Company would have recorded net income of $11.0 million, or $0.25 per share, in the year ended December 31, 2022, as compared to net loss of $2.2 million, or $(0.05) per share, in the prior year.

● Adjusted EBITDA, as detailed in the tables below, was $17.8 million in the year ended December 31, 2022, as compared to $5.4 million in the year ended December 31, 2021, representing an over 3x increase year-over-year, and 14% margins, which was in line with Kamada's annual guidance.

● Cash provided by operating activities was $28.6 million in the year ended December 31, 2022, as compared to cash used in operating activities of ($8.8) million in the prior year.

**Financial Highlights for the Three Months Ended December 31, 2022**

● Total revenues were $45.4 million in the fourth quarter of 2022, a 44% increase from the prior year period. Total revenues during the fourth quarter of 2022 included strong sales from the portfolio of four acquired FDA-approved IgG products.

● Gross profit and gross margins were $15.3 million and 34%, respectively, in the fourth quarter of 2022, compared to $6.6 million and 21%, respectively, reported in the prior year period. The increase in profitability was driven by a positive product sales mix, including sales of the four new IgG products, KEDRAB U.S sales and GLASSIA royalties. Cost of goods sold in the Company's Proprietary segment in the fourth quarter of 2022 included $1.3 million of depreciation expenses associated with intangible assets generated through the IgG products acquisition. Gross profit and gross margins, excluding such intangible assets depreciation, would have been $16.6 million and 37%, respectively.

● Operating expenses, including R&D, S&M, G&A and other expenses, totaled $11.3 million in the fourth quarter of 2022, as compared to $9.9 million in the fourth quarter of 2021. This increase was attributable to increased S&M costs associated with expanded U.S. commercial operations. S&M costs for the fourth quarter of 2022 included $0.4 million of depreciation expenses of intangible assets generated through the IgG products acquisition.

● Finance expense, net for the fourth quarter of 2022 included $0.3 million of expenses associated with the revaluation of the contingent consideration and other long-term liabilities assumed as part of the IgG products acquisition.

● Net income was $2.9 million, or $0.07 per share, in the fourth quarter of 2022. Excluding depreciation expenses of intangible assets mentioned above and finance expense associated with the revaluation of the contingent consideration and other assumed long-term liabilities, the Company would have recorded net income of $5.0 million, or $0.11 per share, in the fourth quarter of 2022, as compared to a net loss of ($5.0) million, or $(0.11) per share, in the fourth quarter of 2021.

● Adjusted EBITDA, as detailed in the tables below, was $7.2 million in the fourth quarter of 2022, as compared to ($1.3) million in the fourth quarter of 2021.

● Cash provided by operating activities was $6.7 million in the fourth quarter of 2022, as compared to cash used in operating activities of ($5.0) million in the fourth quarter of 2021.

**Balance Sheet Highlights**

As of December 31, 2022, the Company had cash, cash equivalents, and short-term investments of $34.3 million, as compared to $18.6 million on December 31, 2021. The increase in Kamada's cash position was driven by continued positive operational cash flows, which is indicative of the significant momentum in the Company's commercial operations.

**Recent Corporate Highlights** 

● Submitted applications to the U.S. Food and Drug Administration (FDA) and to Health Canada to manufacture CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at Kamada's facility in Beit Kama, Israel.

● Reported on progress achieved in the ongoing pivotal Phase 3 clinical trial of inhaled AAT, InnovAATe, including acceleration in trial recruitment, a successful DSMB meeting, encouraging safety data observed to date, and the intention to meet with the FDA and European Medicines Agency during first half of 2023 to discuss study progress and potential opportunities to shorten the regulatory pathway.

**Fiscal Year 2023 Guidance**

Kamada currently expects to generate fiscal year 2023 total revenues in the range of $138 million to $146 million and EBITDA in the range of $22 million to $26 million; mid-point expected EBITDA represents approximately 35% growth year-over-year.

**Conference Call**

Kamada management will host an investment community conference call and webcast with slides on Wednesday, March 15, at 8:30 AM Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) 1 809-406-247 (from Israel) or 1 201-689-8263 (International). The live webcast will be available on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1601498&tp_key=dfb5545156

**Non-IFRS financial measures**

We present EBITDA and adjusted EBITDA, which is defined as net income, plus (i) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization; and (iv) non-cash share-based compensation expenses, because we use this non-IFRS financial measure to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes this non-IFRS financial measure are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company's core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA and adjusted EBITDA are defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, plus non-cash share-based compensation expenses and certain other costs.

**About Kamada** 

Kamada Ltd. (the "Company") is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company's strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company's commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: CYTOGAM®, KEDRAB®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers and during recent years added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA registered plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D). In addition to the Company's commercial operation, it invests in research and development of new product candidates. The Company's leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

**Cautionary Note Regarding Forward-Looking Statements** 

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) 2023 revenue guidance in the range of $138 million to $146 million, 2) 2023 EBITDA guidance in the range of $22 million to $26 million, 3) expected mid-point EBITDA representing approximately 35% growth year over year, 4) expectations that significant multiple catalysts are driving Kamada's annual double-digit growth in the foreseeable years ahead, with significant upside potential and limited downside risks, 5) intention to meet with the FDA and European Medicines Agency during the first half of 2023 to discuss study progress and potential opportunities to shorten the regulatory pathway, and 6) expectation of launching eleven biosimilar products in the Israel market through 2028. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, the continued evolvement of the COVID-19 pandemic, its scope, effect and duration, availability of sufficient raw materials required to maintain manufacturing plans, disruption to the supply chain due to COVID-19 pandemic, continuation of inbound and outbound international delivery routes, impact of the workforce downsizing plan, continued demand for Kamada's products, financial conditions of the Company's customer, suppliers and services providers, Kamada's ability to integrate the new product portfolio into its current product portfolio, Kamada's ability to grow the revenues of this new product portfolio, and leverage and expand its international distribution network, ability to reap the benefits of the recent acquisition of the plasma collection center, including the ability to open additional U.S. plasma centers, and acquisition of the FDA-approved plasma-derived hyperimmune commercial products, the ability to continue enrollment of the pivotal Phase 3 InnovAATe clinical trial, unexpected results of clinical studies, Kamada's ability to manage operating expenses, additional competition in the markets that Kamada competes, regulatory delays, the impacts of the failure of Silicon Valley Bank and recent turmoil in the banking industry, prevailing market conditions and the impact of general economic, industry or political conditions in the U.S., Israel or otherwise, and other risks detailed in Kamada's filings with the U.S. Securities and Exchange Commission (the "SEC") including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC's website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

**CONTACTS:**

Chaime Orlev

Chief Financial Officer

IR@kamada.com

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2022** | **2021** |
|  | **U.S. Dollars in thousands** | **U.S. Dollars in thousands** |
| Assets |  |  |
| <u>Current Assets</u> |  |  |
| Cash and cash equivalents | $34258 | $18587 |
| Trade receivables, net | 27252 | 35162 |
| Other accounts receivables | 8710 | 8872 |
| Inventories | 68785 | 67423 |
| Total Current Assets | 139005 | 130044 |
| <u>Non-Current Assets</u> |  |  |
| Property, plant and equipment, net | 26157 | 26307 |
| Right-of-use assets | 2568 | 3092 |
| Intangible assets, Goodwill and other long-term assets | 147072 | 153663 |
| Contract asset | 7577 | 5561 |
| Total Non-Current Assets | 183374 | 188623 |
| Total Assets | $322379 | $318667 |
| Liabilities |  |  |
| <u>Current Liabilities</u> |  |  |
| Current maturities of bank loans | $4444 | $2631 |
| Current maturities of lease liabilities | 1016 | 1154 |
| Current maturities of other long term liabilities | 29708 | 17986 |
| Trade payables | 32917 | 25104 |
| Other accounts payables | 7585 | 7142 |
| Deferred revenues | 35 | 40 |
| Total Current Liabilities | 75705 | 54057 |
| <u>Non-Current Liabilities</u> |  |  |
| Bank loans | 12963 | 17407 |
| Lease liabilities | 2177 | 3160 |
| Contingent consideration | 17534 | 21995 |
| Other long-term liabilities | 37308 | 43929 |
| Deferred revenues |  | 15 |
| Employee benefit liabilities, net | 672 | 1280 |
| Total Non-Current Liabilities | 70654 | 87786 |
| <u>Shareholder's Equity</u> |  |  |
| Ordinary shares | 11734 | 11725 |
| Additional paid in capital net | 210495 | 210204 |
| Capital reserve due to translation to presentation currency | (3490) | (3490) |
| Capital reserve from hedges | (88) | 54 |
| Capital reserve from share-based payments | 5505 | 4643 |
| Capital reserve from employee benefits | 348 | (149) |
| Accumulated deficit | (48484) | (46163) |
| Total Shareholder's Equity | 176020 | 176824 |
| Total Liabilities and Shareholder's Equity | $322379 | $318667 |

---

**CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME** 

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended** | **For the year ended** | **Three months period ended** | **Three months period ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  | **U.S. Dollars in thousands, other than per share information** | **U.S. Dollars in thousands, other than per share information** | **U.S. Dollars in thousands, other than per share information** | **U.S. Dollars in thousands, other than per share information** |
| Revenues from proprietary products | $102598 | $75521 | $35400 | $18205 |
| Revenues from distribution | 26741 | 28121 | 10039 | 13264 |
| Total revenues | 129339 | 103642 | 45439 | 31469 |
| Cost of revenues from proprietary products | 58229 | 48194 | 20373 | 12589 |
| Cost of revenues from distribution | 24407 | 25120 | 9775 | 12285 |
| Total cost of revenues | 82636 | 73314 | 30148 | 24874 |
| Gross profit | 46703 | 30328 | 15291 | 6595 |
| Research and development expenses | 13172 | 11357 | 2991 | 3448 |
| Selling and marketing expenses | 15284 | 6278 | 4849 | 2475 |
| General and administrative expenses | 12803 | 12636 | 3322 | 3833 |
| Other expenses | 912 | 753 | 111 | 141 |
| Operating income (loss) | 4532 | (696) | 4018 | (3302) |
| Financial income | 91 | 295 | 59 | 18 |
| Income (expenses) in respect of currency exchange differences and derivatives instruments, net | 298 | (207) | (458) | (281) |
| Financial Income (expense) in respect of contingent consideration and other long- term liabilities. | (6266) |  | (342) |  |
| Financial expenses | (914) | (1277) | (331) | (1099) |
| Income before tax on income | (2259) | (1885) | 2946 | (4664) |
| Taxes on income | 62 | 345 | 2 | 345 |
| Net Income (loss) | $(2321) | $(2230) | $2944 | $(5009) |
| Other Comprehensive Income (loss): |  |  |  |  |
| Amounts that will be or that have been reclassified to profit or loss when specific conditions are met |  |  |  |  |
| Gain (loss) on cash flow hedges | (776) |  | 54 | (25) |
| Net amounts transferred to the statement of profit or loss for cash flow hedges | 634 | (303) | 115 | 44 |
| Items that will not be reclassified to profit or loss in subsequent periods: |  |  |  |  |
| Remeasurement gain (loss) from defined benefit plan | 497 | 171 | 136 | 171 |
| Total comprehensive income (loss) | $(1966) | $(2362) | $3249 | $(4819) |
| <u>Earnings per share attributable to equity holders of the Company:</u> |  |  |  |  |
| Basic net earnings per share | $(0.05) | $(0.05) | $0.07 | $(0.11) |
| Diluted net earnings per share | $(0.05) | $(0.05) | $0.07 | $(0.11) |

---

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended** | **For the year ended** | **Three months period ended** | **Three months period ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| <u>Cash Flows from Operating Activities</u> |  |  |  |  |
| Net income (loss) | $(2321) | $(2230) | $2944 | $(5009) |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |  |  |
| Adjustments to the profit or loss items: |  |  |  |  |
| Depreciation and impairment | 12155 | 5609 | 3012 | 1997 |
| Financial expenses (income), net | 6791 | 1189 | 1072 | 1362 |
| Cost of share-based payment | 1153 | 529 | 218 | 25 |
| Taxes on income | 62 | 345 | 2 | 345 |
| Change in employee benefit liabilities, net | (111) | 45 | (5) | (16) |
|  | 20050 | 7717 | 4299 | 3713 |
| Changes in asset and liability items: |  |  |  |  |
| Decrease (increase) in trade receivables, net | 7603 | (12861) | (3141) | (8415) |
| Decrease (increase) in other accounts receivables | (578) | (1634) | (3495) | (3191) |
| Decrease (increase) in inventories | (1361) | (2373) | 4245 | 3590 |
| Decrease (increase) in deferred expenses | (1340) | (6883) | 1256 | (2124) |
| Increase (decrease) in trade payables | 7055 | 7917 | 1160 | 5192 |
| Increase (decrease) in other accounts payables | 290 | (392) | (276) | 1091 |
| Decrease in deferred revenues | (20) | 1815 | (20) | 265 |
|  | 11649 | (14411) | (271) | (3592) |
| Cash received (paid) during the period for: |  |  |  |  |
| Interest paid | (853) | (228) | (303) | (89) |
| Interest received | 97 | 375 | 82 | 18 |
| Taxes paid | (36) | (42) | (9) | (10) |
|  | (792) | 105 | (230) | 81 |
| <u>Net cash provided by (used in) operating activities</u> | $28586 | $(8819) | $6742 | $(4969) |

---

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended** | **For the year ended** | **Three months period ended** | **Three months period ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  | **U.S Dollars In thousands** | **U.S Dollars In thousands** | **U.S Dollars In thousands** | **U.S Dollars In thousands** |
| <u>Cash Flows from Investing Activities</u> |  |  |  |  |
| Investment in short term investments, net | $- | $39083 | $- | $- |
| Purchase of property and equipment and intangible assets | (3784) | (3730) | (977) | (744) |
| Business combination | - | (96403) | - | (94999) |
| Net cash provided by (used in) investing activities | (3784) | (61050) | (977) | (95743) |
| <u>Cash Flows from Financing Activities</u> |  |  |  |  |
| Proceeds from exercise of share base payments | 9 | 19 | 2 | 5 |
| Receipt of long-term loans |  | 20000 |  | 20000 |
| Repayment of lease liabilities | (1098) | (1221) | (256) | (318) |
| Repayment of long-term loans | (2628) | (205) | (1111) | 16 |
| Repayment of other long-term liabilities | (5626) | - | (1507) | - |
| Net cash provided by (used in) financing activities | (9343) | 18593 | (2872) | 19703 |
| Exchange differences on balances of cash and cash equivalent | 212 | (334) | 113 | (244) |
| Increase (decrease) in cash and cash equivalents | 15671 | (51610) | 3006 | (81253) |
| <u>Cash and cash equivalents at the beginning of the period</u> | 18587 | 70197 | 31252 | 99840 |
| <u>Cash and cash equivalents at the end of the period</u> | $34258 | $18857 | $34258 | $18587 |
| <u>Significant non-cash transactions</u> |  |  |  |  |
| Right-of-use asset recognized with corresponding lease liability | $551 | $845 | $526 | $76 |
| Purchase of property and equipment and Intangible assets | $618 | $1001 | $134 | $649 |

---

**NON-IFRS MEASURES - EBITDA**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the year ended** | **For the year ended** | **Three months period ended** | **Three months period ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  | **In thousands** | **In thousands** | **In thousands** | **In thousands** |
| Net income | $(2321) | $(2230) | $2944 | $(5009) |
| Taxes on income | 62 | 345 | 2 | 345 |
| Financial expense (income), net | 6791 | 1189 | 1072 | 1362 |
| Depreciation and amortization expense | 12155 | 5609 | 3012 | 1997 |
| Non-cash share-based compensation expenses | 1153 | 529 | 218 | 25 |
| Adjusted EBITDA | $17840 | $5442 | $7248 | $(1280) |

---